Tumour necrosis factor-α as a therapeutic target in asthma

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 309-316

  Morjaria, Jaymin B ^a   Babu, K Suresh ^a   Holgate, Stephen T ^a   Polosa, Riccardo ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BRONCHODILATING AGENT; CELL SURFACE RECEPTOR; CORTICOSTEROID; CYTOKINE; EPIDERMAL GROWTH FACTOR; ETANERCEPT; FIBROBLAST GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TENASCIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DEMYELINATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TARGETING; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HEMIPLEGIA; HUMAN; INFLAMMATION; INJECTION SITE REACTION; NEUROTOXICITY; PATHOGENESIS; RESPIRATORY TRACT INFECTION; REVIEW; TH2 CELL; TUBERCULOSIS; UPREGULATION;

EID: 33751265847     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.09.007     Document Type: Review

References (80)

1. The ENFUMOSA Study Group (2003) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur. Respir. J. 22, 470-477.
2. Serra-Batlles J., et al. Costs of asthma according to the degree of severity. Eur. Respir. J. 12 (1998) 1322-1326
3. Godard P., et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur. Respir. J. 19 (2002) 61-67
4. Antonicelli L., et al. Asthma severity and medical resource utilisation. Eur Respir J. 23 5 (2004) 723-729
5. Holgate S., and Polosa R. The mechanisms, diagnosis and management of severe asthma in adults. Lancet 368 (2006) 705-814
6. Bodey K.J., et al. Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. Allergy 54 (1999) 1083-1093
7. Hamilos D.L., et al. Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease. J. Allergy Clin. Immunol. 103 1 Pt 1 (1999) 79-87
8. Wilson S.J., et al. Effects of budesonide and formoterol on NF-kB, adhesion molecules, and cytokines in asthma. Am. J. Respir. Crit. Care Med. 164 (2001) 1047-1052
9. Kay A.B. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 344 (2001) 30-37
10. Jatakanon A., et al. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. 160 5 Pt 1 (1999) 1532-1539
11. Hamilton L.M., et al. The role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clin. Exp. Allergy 33 (2003) 233-240
12. Holgate S.T., et al. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J. Allergy Clin. Immunol. 105 (2000) 193-224
13. Davies D.E., et al. The epidermal growth factor receptor and its ligand family: their potential role in repair and remodelling in asthma. Allergy 54 (1999) 771-783
14. Knight D.A., and Holgate S.T. The airway epithelium: structural and functional properties in health and disease. Respirology 8 (2003) 432-446
15. Holgate S.T., et al. Epithelial-mesenchymal communication in the pathogenesis of chronic asthma. Proc Am Thorac Soc. 1 (2004) 93-98
16. Marchac V., et al. Thoracic CT in pediatric patients with difficult-to-treat asthma. Am. J. Roentgenol. 179 (2002) 1245-1252
17. Russo C., and Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin. Sci. (Lond.) 109 (2005) 135-142
18. Ohkawara Y., et al. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering. Am. J. Respir. Cell Mol. Biol. 7 (1992) 385-392
19. Finotto S., et al. TNF-alpha production by eosinophils in upper airways inflammation (nasal polyposis). J. Immunol. 153 (1994) 2278-2289
20. Abdelaziz M.M., et al. The effect of conditioned medium from cultured human bronchial epithelial cells on eosinophil and neutrophil chemotaxis and adherence in vitro. Am. J. Respir. Cell Mol. Biol. 13 (1995) 728-737
21. Bradding P., et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 10 (1994) 471-480
22. Cembrzynska-Nowak M., et al. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am. Rev. Respir. Dis. 147 (1993) 291-295
23. Gosset P., et al. Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 88 4 (1991) 561-571
24. Gosset P., et al. Tumor necrosis factor alpha and interleukin-6 production by human mononuclear phagocytes from allergic asthmatics after IgE-dependent stimulation. Am. Rev. Respir. Dis. 146 (1992) 768-774
25. Howarth P.H., et al. Tumour necrosis factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 60 12 (2005) 1012-1018
26. Broide D.H., et al. Cytokines in symptomatic asthma airways. J. Allergy Clin. Immunol. 89 (1992) 958-967
27. Tillie-Leblond I., et al. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am. J. Respir. Crit. Care Med. 159 (1999) 487-494
28. Lilly C.M., et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J. Clin. Invest. 99 (1997) 1767-1773
29. Salvi S., et al. Interleukin-5 production by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 20 (1999) 984-991
30. Bedard M., et al. Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 9 (1993) 455-462
31. Tosi M.F., et al. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. Am. J. Respir. Cell Mol. Biol. 7 (1992) 214-221
32. Richter M., et al. Zinc chelators inhibit eotaxin, RANTES, and MCP-1 production in stimulated human airway epithelium and fibroblasts. Am J Physiol Lung Cell Mol Physiol 285 3 (2003) L719-L729
33. Thomas P.S. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 79 2 (2001) 132-140
34. Yamamoto H., et al. Differential regulation of eosinophil adhesion and transmigration by pulmonary microvascular endothelial cells. J. Immunol. 161 (1998) 971-977
35. Panettieri Jr. R.A., et al. Activation of cAMP-dependent pathways in human airway smooth muscle cells inhibits TNF-alpha-induced ICAM-1 and VCAM-1 expression and T lymphocyte adhesion. J. Immunol. 154 (1995) 2358-2365
36. Kips J.C., et al. Tumor necrosis factor causes bronchial hyperresponsiveness in rats. Am. Rev. Respir. Dis. 145 2 Pt 1 (1992) 332-336
37. Thomas P.S., et al. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am. J. Respir. Crit. Care Med. 152 (1995) 76-80
38. Levine S.J., et al. Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 12 (1995) 196-204
39. Shirasaki H., et al. Tumor necrosis factor increases MUC1 mRNA in cultured human nasal epithelial cells. Acta Otolaryngol. 123 (2003) 524-531
40. Song K.S., et al. Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J. Biol. Chem. 278 (2003) 23243-23250
41. Kwon S., and George S.C. Synergistic cytokine-induced nitric oxide production in human alveolar epithelial cells. Nitric Oxide 3 (1999) 348-357
42. Harkonen E., et al. Modulation of fibronectin and tenascin production in human bronchial epithelial cells by inflammatory cytokines in vitro. Am. J. Respir. Cell Mol. Biol. 13 (1995) 109-115
43. Zhu Z., et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103 6 (1999) 779-788
44. Schwingshackl A., et al. Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha. J. Allergy Clin. Immunol. 104 (1999) 983-989
45. Nakamura Y., et al. Ets-1 regulates TNF-alpha-induced matrix metalloproteinase-9 and tenascin expression in primary bronchial fibroblasts. J. Immunol. 172 (2004) 1945-1952
46. Elias J.A., et al. Airway remodeling in asthma. J. Clin. Invest. 104 (1999) 1001-1006
47. Paulsson Y., et al. Tumor necrosis factor-induced expression of platelet-derived growth factor A-chain messenger RNA in fibroblasts. Exp. Cell Res. 180 (1989) 490-496
48. Palombella V.J., et al. Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor. J. Cell Physiol. 135 (1988) 23-31
49. Amrani Y., et al. Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma?. Respir. Res. 1 (2000) 49-53
50. Sukkar M.B., et al. Tumour necrosis factor-alpha potentiates contraction of human bronchus in vitro. Respirology 6 (2001) 199-203
51. Wilkinson M.F., et al. Interleukin-1beta, tumor necrosis factor-alpha, and LPS enhance calcium channel current in isolated vascular smooth muscle cells of rat tail artery. FASEB J. 10 (1996) 785-791
52. Johnson S.R., and Knox A.J. Synthetic functions of airway smooth muscle in asthma. Trends Pharmacol. Sci. 18 8 (1997) 288-292
53. Anticevich S.Z., et al. Induction of human airway hyperresponsiveness by tumour necrosis factor-alpha. Eur. J. Pharmacol. 284 (1995) 221-225
54. Thomas P.S., and Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 57 (2002) 774-778
55. Gosset P., et al. Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors. J. Allergy Clin. Immunol. 103 2 Pt1 (1999) 289-297
56. Shull M.M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693-699
57. Babu K.S. et al. (2004) Effects of blocking tumour necrosis factor alpha on responses of bronchial explants from the subjects with moderately severe asthma. Am. J. Respir. Crit. Care Med. 169(7), A801.
58. Scichilone N., et al. Monitoring response to treatment in asthma management: food for thought. Clin. Exp. Allergy 34 (2004) 1168-1177
59. Rouhani F.N., et al. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir. Med. 99 (2005) 1175-1182
60. Holgate S.T. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 28 4-5 (2004) 152-157
61. Berry M.A., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N. Engl. J. Med. 354 (2006) 697-708
62. Mohler K.M., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151 (1993) 1548-1561
63. Moreland L.W., et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23 (1996) 1849-1855
64. Juniper E.F., et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Rev. Respir. Dis. 142 (1990) 832-836
65. Juniper E.F., et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47 (1992) 76-83
66. Erin E.M., et al. The effects of a monoclonal antibody directed against tumour necrosis factor-{alpha} (TNF-{alpha}) in asthma. Am. J. Respir. Crit. Care Med. 174 7 (2006) 753-762
67. Fleischmann R., et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann. Rheum. Dis. 65 (2006) 379-384
68. Keystone E.C. Safety of biologic therapies-an update. J. Rheumatol. Suppl. 74 (2005) 8-12
69. Weisman M.H. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J. Rheumatol. Suppl. 65 (2002) 33-38
70. Keane J., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345 (2001) 1098-1104
71. Ellerin T., et al. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 48 (2003) 3013-3022
72. Mohan N., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44 (2001) 2862-2869
73. Brown S.L., et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46 (2002) 3151-3158
74. Mariette X., et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99 (2002) 3909-3915
75. Sarzi-Puttini P., et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun. Rev. 4 (2005) 153-161
76. Bayley J.P., et al. Is there a future for TNF promoter polymorphisms?. Genes Immun. 5 (2004) 315-329
77. Randolph D.A., et al. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J. Clin. Invest. 104 (1999) 1021-1029
78. Moffatt M.F., et al. Extended tumour necrosis factor/HLA-DR haplotypes and asthma in an Australian population sample. Thorax 54 (1999) 757-761
79. Li Kam Wa T.C., Mansur A.H., et al. Association between -308 tumour necrosis factor promoter polymorphism and bronchial hyperreactivity in asthma. Clin. Exp. Allergy 29 (1999) 1204-1208
80. Mariette X. Emerging biological therapies in rheumatoid arthritis. Joint Bone Spine 71 (2004) 470-474